FIGARO: A Randomised Trial of the FLAMSA-BU CondItioning ReGimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia UndeRgoing AllOgeneic Stem Cell Transplantation

Trial Overview and Summary

Treatment options for older adults with Acute Myeloid Leukaemia and Myelodysplasia are limited. Although stem cell transplantation remains one of the most effective treatments it is associated with severe side effects which have until recently prevented its use in older adults. Recent studies in Europe appear to have identified a new form of transplant regimen which is associated with improved outcomes in older patients; we therefore propose to compare the new FLAMSA-BU transplant with currently used transplant regimens, allowing us to compare the benefits in terms of toxicity, disease relapse and overall survival.

Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Chief Investigator: Professor Charles Craddock
Sponsor: The University of Birmingham  
Funders: Bloodwise  
Disease Site: Acute Myeloid Leukaemia and Myelodysplasia
Trial Type: Clinical Trial of an Investigational Medicinal Product
Status: Follow-up  
UKCRN Study ID: 14772
Open to new sites? No  
Recruitment start date: 16/10/2013
Recruitment end date: 08/02/2017
CRCTU Trial Management Team: Haematology  
Trial E-mail Address:  

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their healthcare professional or refer to CancerHelp website [opens new page].

More information

Cancer Help (Cancer Research UK) [opens new page]